Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA.
Columbia University College of Physicians-St. Luke's-Roosevelt Hospital Center, New York, NY, USA.
Crit Rev Oncol Hematol. 2014 May;90(2):152-64. doi: 10.1016/j.critrevonc.2013.11.007. Epub 2013 Dec 1.
The role of the VEGF signaling pathway in angiogenesis has been extensively investigated, and many new targeted anti-angiogenic drugs have evolved from this knowledge. The recent approval and introduction of these anti-neoplastic drugs has revolutionized the treatment of many types of cancers, but has also revealed numerous toxicities to the skin and its adnexae. Since these cutaneous side effects may have a significant impact on the physical, emotional and psychosocial health of patients, it is important for dermatologists and oncologists alike to be aware of the cutaneous complications of these drugs in order to properly diagnose and treat them. This review will detail the presentation of the cutaneous complications of the anti-angiogenic drugs, most notably bevacizumab, sorafenib and sunitinib, and shed light on the management of such adverse reactions.
VEGF 信号通路在血管生成中的作用已被广泛研究，许多新的靶向抗血管生成药物就是由此发展而来。这些抗肿瘤药物的最近批准和引入已经彻底改变了许多类型癌症的治疗方法，但也暴露出对皮肤及其附属物的许多毒性。由于这些皮肤副作用可能对患者的身体、情感和社会心理健康产生重大影响，皮肤科医生和肿瘤学家都了解这些药物的皮肤并发症非常重要，以便正确诊断和治疗它们。本综述将详细介绍抗血管生成药物（尤其是贝伐珠单抗、索拉非尼和舒尼替尼）的皮肤并发症表现，并探讨此类不良反应的管理。
